Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Income from Continuing Operations (2023 - 2025)

Mangoceuticals' Income from Continuing Operations history spans 3 years, with the latest figure at 7618776.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 281.0% year-over-year to 7618776.0; the TTM value through Sep 2025 reached 19822681.0, down 112.54%, while the annual FY2024 figure was 8707226.0, 5.48% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 7618776.0 at Mangoceuticals, down from 5415820.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1799460.0 in Q3 2023 and bottomed at 7618776.0 in Q3 2025.
  • The 3-year median for Income from Continuing Operations is 2391319.0 (2024), against an average of 3253975.27.
  • The largest annual shift saw Income from Continuing Operations rose 24.12% in 2024 before it plummeted 281.0% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 2568047.0 in 2023, then grew by 24.12% to 1948596.0 in 2024, then tumbled by 290.99% to 7618776.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Income from Continuing Operations are 7618776.0 (Q3 2025), 5415820.0 (Q2 2025), and 4839489.0 (Q1 2025).